4:40 PM ET
8-K
Leadership Change
Enliven Therapeutics Leadership Change
Enliven Therapeutics appointed Kristine Ball to its Board of Directors and Audit Committee, effective October 14, 2026. Ms. Ball, an experienced biopharmaceutical executive, joins as the company prepares to initiate a pivotal Phase 3 trial for relcobatinib. Her compensation includes $55,000 in annual cash fees and stock options valued at approximately $650,000.
- Counterparty
- Kristine Ball